Get the latest news, insights, and market updates on MMSI (Merit Medical Systems, Inc.). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Merit Medical Releases 24-Month Efficacy Results from the Randomized Arteriovenous Fistula (AVF) Arm of the WRAPSODY Arteriovenous Access Efficacy (WAVE) Trial
The target lesion primary patency (TLPP)1 and access circuit primary patency (ACPP)2 of the WRAPSODY® Cell-Impermeable Endoprosthesis (CIE) remain superior to percutaneous transluminal angioplasty (PTA) through 24 monthsThe clinical improvements associated with the WRAPSODY CIE are projected to improve the interventional landscape for hemodialysis patients who experience venous outflow obstructions SOUTH JORDAN, Utah, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), Nov 5, 2025 - $MMSI
Merit Medical Releases 24-Month Efficacy Results from the Single-Arm Arteriovenous Graft (AVG) Cohort of the WRAPSODY Arteriovenous Access Efficacy (WAVE) Trial
At 24 months, the target lesion primary patency (TLPP)1 was 41.7%At 24 months, the access circuit primary patency (ACPP)2 was 25.7% SOUTH JORDAN, Utah, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced 24-month efficacy findings from the non-randomized AVG cohort of the WAVE trial. Results of the AVG cohort were presented during the Late-Breaking Clinical Trials session at the annual VIVA Foundation3 Venous End Nov 3, 2025 - $MMSI
Merit Medical Systems (MMSI) Margin Moderation Tests Bullish Growth Narratives
Merit Medical Systems (MMSI) delivered EPS growth forecasts of 16.25% annually, with net profit margins currently at 8.3%, slightly below last year’s 9%. The company’s earnings grew by 1.4% over the past year, trailing its five-year average growth rate of 40.5% per year. Revenue is projected to rise by 6.1% annually, lagging behind the broader US market expectation of 10.3%. Investors are likely to weigh this continued profitability and ongoing growth against the moderation in margins and the... Nov 1, 2025 - $MMSI
MMSI Q3 Deep Dive: Product Innovation and Execution Drive Outperformance
Medical device company Merit Medical Systems (NASDAQ:MMSI) beat Wall Street’s revenue expectations in Q3 CY2025, with sales up 13% year on year to $384.2 million. The company’s full-year revenue guidance of $1.51 billion at the midpoint came in 0.6% above analysts’ estimates. Its non-GAAP profit of $0.92 per share was 11.4% above analysts’ consensus estimates. Oct 31, 2025 - $MMSI
Why Are Merit Medical Systems (MMSI) Shares Soaring Today
Shares of medical device company Merit Medical Systems (NASDAQ:MMSI) jumped 6% in the afternoon session after the company reported strong third-quarter 2025 financial results that beat Wall Street expectations and raised its full-year guidance. Oct 31, 2025 - $MMSI
Merit Medical (MMSI) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Merit Medical (MMSI) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. Oct 30, 2025 - $MMSI
Merit Medical Systems (NASDAQ:MMSI) Delivers Strong Q3 Numbers, Stock Soars
Medical device company Merit Medical Systems (NASDAQ:MMSI) announced better-than-expected revenue in Q3 CY2025, with sales up 13% year on year to $384.2 million. The company’s full-year revenue guidance of $1.51 billion at the midpoint came in 0.6% above analysts’ estimates. Its non-GAAP profit of $0.92 per share was 11.4% above analysts’ consensus estimates. Oct 30, 2025 - $MMSI
Merit Medical: Q3 Earnings Snapshot
The South Jordan, Utah-based company said it had profit of 46 cents per share. Earnings, adjusted for non-recurring costs and stock option expense, were 92 cents per share. The results topped Wall Street expectations. Oct 30, 2025 - $MMSI
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple